CRISPR company Intellia prices IPO

Share this article

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) raised $108 million on Thursday through the sale of 6 million shares at $18 in an IPO underwritten by Credit Suisse, Jefferies, Leerink and Wedbush PacGrow. In a regulatory filing earlier Thursday, Intellia said it hoped to sell 5 million shares at $16-$18. Intellia is one of a handful of companies developing products using CRISPR-Cas9 (CRISPR-associated protein 9) genome editing technology. The first to go public, Editas Medicine Inc. (NASDAQ:EDIT), closed at $31.99 on Thursday, up 100% from its Feb. 2 IPO price of $16. Intellia expects its shares to begin trading on Friday. Adapted from BioCentury.